Background: Factors predicting survival in men with lymph node-positive prostate cancer are still poorly defined. Patients and Methods: 193 prostate cancer patients with histopathologically proven lymph node involvement with a median follow-up of 7.3 years were studied. 94% of patients received immediate hormonal therapy. Kaplan-Meier curves were calculated to evaluate overall survival rates and compared with the log-rank test. Cumulative disease-specific and competing mortality rates were calculated by competing risk analysis and compared with the Pepe-Mori test. Cox proportional hazard models were used to determine the independent significance of predictors of all-cause mortality. Results: Age (70 years or older vs. younger), Gleason score (8–10 vs. 7 or lower) and the number of involved nodes (3 or more vs. 1–2) were identified as independent predictors of all-cause mortality. When patients with 0–1 of these risk factors were compared with those with 2–3 risk factors, all-cause (rates after 10 years 21% vs. 71%, p < 0.0001), disease-specific (12 vs. 37%, p = 0.009) and competing mortality (9 vs. 33%, p = 0.02) differed significantly. Conclusions: Some of the excess mortality in patients with poor-risk lymph node-positive prostate cancer may be attributed to increased competing mortality, possibly caused by an interaction between comorbid diseases and hormonally treated persistent or progressive prostate cancer.

Keywords:
Urological neoplasms, Prostate cancer, Lymph nodes, Radical prostatectomy, Prognostic factors, Overall survival, Disease-specific survival, Competing mortality
1.
Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics. The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212–236.
2.
Fleischmann A, Rocha C, Saxer-Sekulic N, Zlobec I, Sauter G, Thalmann GN: High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Arch 2011;458:741–748.
3.
American Society of Anesthesiologists: ASA physical status classification system. Available from: http://www.asahq.org/clinical/physicalstatus.htm (accessed February 19, 2012).
4.
The Criteria Committee of the New York Heart Association: Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels, ed 9. Boston, Little, Brown, 1994, pp 253–256.
5.
Canadian Cardiovascular Society: Canadian Cardiovascular Society grading of angina pectoris. Available from: http://www.ccs.ca/download/position_statements/Grading%20of%20Angina.pdf (accessed February 19, 2012).
6.
Charlson ME, Pompei P, Ales KL, MacKenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987;40:373–383.
7.
Pintilie M: Competing Risks: A Practical Perspective. Chichester, Wiley, 2006, pp 195–207.
8.
Briganti A, Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N: Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node-positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009;55:261–270.
9.
Messing EM, Manola J, Yao J, Kiernan M, Crawford D, Wilding G, di’SantAgnese PA, Trump D, Eastern Cooperative Oncology Group Study EST 3886: Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7:472–479.
10.
Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE: Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008;54:344–352.
11.
Da Pozzo LF, Cozzarini C, Briganti A, Suardi N, Salonia A, Bertini R: Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. Eur Urol 2009;55:1003–1011.
12.
Fleischmann A, Schobinger S, Schumacher M, Thalmann GN, Studer UE: Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 2009;69:352–362.
13.
Steuber T, Budäus L, Walz J, Zorn KC, Schlomm T, Chun F, Ahyai S, Fisch M, Sauter G, Huland H, Graefen M, Haese A: Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study. BJU Int 2010;107:1755–1761.
14.
Stephenson AJ, Kattan MW, Eastham JA, Bianco FJ Jr, Yossepowitch O, Vickers AJ, et al: Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 2009;27:4300–4305.
15.
Eggener SE, Scardino PT, Walsh PC, Han M, Partin AW, Trock BJ, Feng Z, Wood DP, Eastham JA, Yossepowitch O, Rabah DM, Kattan MW, Yu C, Klein EA, Stephenson AJ: Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011;185:869–875.
16.
Barry MJ, Albertsen PC, Bagshaw MA, Blute ML, Cox R, Middleton RG, Gleason DF, Zincke H, Bergstralh EJ, Jacobsen SJ: Outcomes for men with clinically nonmetastatic prostate carcinoma managed with radical prostatectomy, external beam radiotherapy, or expectant management: a retrospective analysis. Cancer 2001;91:2302–2314.
17.
Guzzo TJ, Dluzniewski P, Orosco R, Platz EA, Partin AW, Han M: Prediction of mortality after radical prostatectomy by Charlson comorbidity index. Urology 2010;76:553–558.
18.
Froehner M, Koch R, Litz RJ, et al: Re: Guzzo et al.: prediction of mortality after radical prostatectomy by Charlson comorbidity index. (Urology 2012;76:553–557). Urology 2010;76:1522.
19.
D’Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW: Androgen suppression and radiation vs radiation alone for prostate cancer. A randomized trial. JAMA 2008;299:289–295.
20.
Engel J, Bastian PJ, Baur H, Chaussy C, Gschwend JE, Oberneder R: Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754–761.
21.
Briganti A, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M: Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2–4 pN+ prostate cancer: Results of a matched analysis. Eur Urol 2011;59:832–840.
22.
Bullock MJ, Srigley JR, Klotz LH, Goldenberg SL: Pathologic effects of neoadjuvant cyproterone acetate on nonneoplastic prostate, prostatic intraepithelial neoplasia, and adenocarcinoma. A detailed analysis of radical prostatectomy specimens from a randomized trial. Am J Surg Pathol 2002;26:1400–1413.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.